文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

静脉维生素C干预脓毒症患者的疗效:基于随机对照试验的系统评价与Meta分析

Efficacy of intravenous vitamin C intervention for septic patients: A systematic review and meta-analysis based on randomized controlled trials.
PubMed 文献 · Am J Emerg Med · 2021-08-12
一句话结论Meta分析提示单用静脉维生素C可能降低脓毒症患者短期死亡率,但整体证据质量有限,需更多高质量RCT验证。

该系统评价与Meta分析共纳入10项RCT、1400例脓毒症或脓毒性休克患者,评估静脉补充维生素C的疗效。结果显示静脉维生素C可改善72小时内SOFA评分变化(RR=1.32,95%CI 0.80–1.85,P<0.0001),但短期死亡率(28–30天)、长期死亡率(90天)、住院时长、无呼吸机天数及ICU时长两组间无差异。亚组分析显示单用静脉维生素C可降低短期死亡率(RR=0.61,95%CI 0.47–0.79,P=0.0002)。作者认为单用静脉维生素C可能降低短期死亡率并保护器官功能,但因纳入研究数量和质量有限,结论需更多大规模高质量RCT验证。

要点

  • 纳入10项RCT共1400例脓毒症或脓毒性休克患者,静脉维生素C可改善72小时内SOFA评分变化(RR=1.32,95%CI 0.80–1.85,P<0.0001)。
  • 整体分析中静脉维生素C对短期死亡率(28–30天)无显著影响(RR=0.83,95%CI 0.65–1.05,P=0.11)。
  • 亚组分析显示单用静脉维生素C可降低短期死亡率(RR=0.61,95%CI 0.47–0.79,P=0.0002)。
  • 长期死亡率(90天)、住院时长、无呼吸机天数及ICU时长两组间无差异。
  • 作者指出因纳入研究数量和质量有限,上述结论需更多大规模高质量RCT验证。

适用人群与场景

  • 脓毒症或脓毒性休克患者(纳入10项RCT共1400例参与者)。

研究设计与关键结果

  • 系统评价与Meta分析,纳入10项RCT共1400例脓毒症或脓毒性休克患者,检索MEDLINE、EmBase、Web of Science、万方数据及CNKI从2000年1月至2021年3月的文献。
  • 静脉维生素C可改善72小时内SOFA评分变化(ΔSOFA)(RR=1.32,95%CI 0.80–1.85,P<0.0001)。
  • 短期死亡率(28–30天)两组无差异(RR=0.83,95%CI 0.65–1.05,P=0.11)。
  • 长期死亡率(90天)两组无差异(RR=1.16,95%CI 0.82–1.66,P=0.40)。
  • 住院时长两组无差异(RR=0.15,95%CI -0.73–1.03,P=0.55)。
  • 无呼吸机天数两组无差异(RR=0.09,95%CI -0.24–0.42,P=0.60)。
  • ICU时长两组无差异(RR=0.22,95%CI -0.13–0.57,P=0.22)。
  • 亚组分析显示单用静脉维生素C可降低短期死亡率(28–30天)(RR=0.61,95%CI 0.47–0.79,P=0.0002)。

证据类型、等级与局限

  • 证据类型:基于随机对照试验的系统评价与Meta分析。
  • 局限:作者指出因纳入研究的数量和质量有限,上述结论需更多大规模高质量随机对照试验验证。

对床旁实践的改变

  • 作者认为单用静脉维生素C治疗可能降低脓毒症患者短期死亡率,并可能保护器官功能。
  • 作者指出上述结论需更多大规模高质量随机对照试验验证。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The role of vitamin C in sepsis is still controversial, we aimed to systematically review the efficacy of intravenous vitamin C supplementation in the treatment of sepsis.

METHODS: MEDLINE, EmBase, Web of Science, WanFang Data and CNKI were comprehensively searched to collect randomized controlled trails (RCTs) of vitamin C supplementation for patients with sepsis or sepsis shock from January 2000 to March 2021. Two researchers independently screened the literature, extracted the data and accessed the risk of bias in the included studies; meta-analysis was then performed by using Revman 5.4 software.

RESULTS: A total of 10 RCTs involving 1400 participants were included. The results of meta-analysis showed that intravenous vitamin C supplementation can improve SOFA (ΔSOFA) within 72 h [RR = 1.32,95% CI(0.80,1.85), P < 0.0001] of septic patients. There were no difference on short term mortality (28-30d)[RR = 0.83,95% CI(0.65,1.05), P = 0.11], long term mortality (90d) [RR = 1.16,95% CI(0.82,1.66), P = 0.40], hospital LOS[RR = 0.15,95% CI(-0.73,1.03), P = 0.55], ventilator-free days[RR = 0.09,95% CI(-0.24,0.42), P = 0.60], ICU-LOS[RR = 0.22,95% CI(-0.13,0.57), P = 0.22], between two groups. The results of Subgroup analysis showed that intravenous vitamin C alone can reduce the risk of short term mortality (28-30d) [RR = 0.61,95% CI(0.47,0.79), P = 0.0002]of sepsis patients.

CONCLUSION: Based on current RCTs, our work indicated that mono-intravenous vitamin C therapy may reduce short-term mortality of sepsis patients, and it may protect organ functions. Due to the limitation of the quantity and quality of included studies, the above conclusions need to be verified by more large scale and high quality randomized control trials.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Li T, Zeng J, Li DH, et al. Efficacy of intravenous vitamin C intervention for septic patients: A systematic review and meta-analysis based on randomized controlled trials. Am J Emerg Med. 2021. PMID: 34416515. doi:10.1016/j.ajem.2021.08.012

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。